Expanding Global Market Share in Blood Coagulation Testing
First written in FY2017. 3 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2025-H1.
1 other company's latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「Finally, we launched the HISCL™ HIT IgG Reagent in the domestic market on 27 September 2024. The reagent measures IgG antibodies against complexes of platelet factor 4 and heparin.」
As part of our product rollout aimed at expanding our share in the blood coagulation testing field, we launched the HISCL™ HIT IgG reagent for HIT diagnosis in Japan. - FY2023AdvancedAnnual report
「In the blood coagulation testing field, we aim to further enhance customer value through a collaborative framework under a global OEM agreement with Siemens Healthcare Diagnostics Inc., involving the reciprocal supply of instruments and reagents.」
Our global alliance with Siemens developed into a collaborative framework involving reciprocal OEM supply of instruments and reagents and global sales under each company’s brand. - FY2021AdvancedAnnual report
「In the blood coagulation testing field, we launched the fully automated blood coagulation analyzers CN-6500/CN-3500 in Japan to achieve further efficiency gains and improve quality. Under our global alliance with Siemens Healthcare Diagnostics Inc. covering blood coagulation testing products, we renewed the agreement, including a review of the products and territories covered. We will strengthen sales of the fully automated CN-series blood coagulation analyzers and continue proposing a broad range of solutions to customers worldwide.」
We launched CN-6500/CN-3500 in Japan, renewed our global alliance with Siemens and strengthened sales of the CN series. - FY2020RestatedAnnual report
「In the blood coagulation testing field, we aim to expand our market share by accelerating the adoption of the CN-6000/CN-3000 fully automated blood coagulation analyzers, partnering with Siemens, and expanding our proprietary reagent portfolio.」
The policy of expanding our share in the blood coagulation field through CN-6000/CN-3000, our alliance with Siemens and our in-house reagent portfolio has been reiterated. - FY2018RestatedAnnual report
「In the blood coagulation testing field, we will continue our global expansion by leveraging our alliance with Siemens, while accelerating the introduction of fibrinolysis reagents used to test coagulation disorders and thrombosis, with the aim of increasing our market share.」
The policy of expanding our share in the blood coagulation testing field through our alliance with Siemens and the introduction of fibrinolysis reagents has been reiterated. - FY2017First statedAnnual report
「In the blood coagulation testing field, we will continue our global expansion by leveraging our alliance with Siemens, while accelerating the introduction of fibrinolysis reagents used to test coagulation disorders and thrombosis, with the aim of increasing our market share.」
For the first time, the Company explicitly stated its goal of expanding its global share in the blood coagulation testing field through its alliance with Siemens and the introduction of fibrinolysis reagents.